Natalie Kenny

Natalie Kenny began their work experience as an Undergraduate Research Assistant at Universidad de Extremadura in 2004. Natalie then worked as a Graduate Research Assistant at The Johns Hopkins University in 2006. In 2007, they became a Graduate Researcher at St George's medical school and later joined Pfizer as a Scientist Supervisor. In 2010, Natalie started their role as a PhD Researcher in Translational Medicine at Cranfield University, and in 2013, they became a Fellow of Nanotoxicology at the Institute of Environment and Health. In 2014, Natalie joined Charles River Laboratories as a Senior Scientist and also became the Managing Director at BioGrad. In 2021, they were promoted to the CEO of the BioGrad Group.

Natalie Kenny completed their PhD in Translational Medicine with a focus on Pharmaceutics and Drug Design from Cranfield University, during the period of 2010-2013. Prior to that, they pursued a course in infectious disease mapping at the London School of Hygiene and Tropical Medicine, University of London, in the year 2005. Natalie had previously studied Biology/Biological Sciences, General at the University of Central Lancashire from 2001 to 2004.